Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Purchased by Mariner LLC

Mariner LLC grew its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 12.5% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 17,983 shares of the company’s stock after buying an additional 2,004 shares during the period. Mariner LLC’s holdings in Protagonist Therapeutics were worth $694,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in PTGX. Barclays PLC increased its position in Protagonist Therapeutics by 223.6% during the 3rd quarter. Barclays PLC now owns 126,995 shares of the company’s stock worth $5,714,000 after purchasing an additional 87,755 shares in the last quarter. Franklin Resources Inc. boosted its position in Protagonist Therapeutics by 127.2% during the third quarter. Franklin Resources Inc. now owns 81,591 shares of the company’s stock worth $3,782,000 after acquiring an additional 45,674 shares during the last quarter. Principal Financial Group Inc. grew its stake in Protagonist Therapeutics by 3,099.4% in the 3rd quarter. Principal Financial Group Inc. now owns 320,832 shares of the company’s stock worth $14,437,000 after acquiring an additional 310,804 shares during the period. FNY Investment Advisers LLC acquired a new position in Protagonist Therapeutics in the 4th quarter valued at $38,000. Finally, Assenagon Asset Management S.A. purchased a new position in shares of Protagonist Therapeutics during the 4th quarter worth $2,016,000. 98.63% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Protagonist Therapeutics news, CFO Asif Ali sold 1,756 shares of the stock in a transaction on Tuesday, April 22nd. The shares were sold at an average price of $46.00, for a total transaction of $80,776.00. Following the transaction, the chief financial officer now directly owns 61,065 shares in the company, valued at $2,808,990. This represents a 2.80 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Dinesh V. Ph D. Patel sold 5,359 shares of the business’s stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $38.18, for a total transaction of $204,606.62. Following the completion of the sale, the chief executive officer now directly owns 540,260 shares of the company’s stock, valued at $20,627,126.80. The trade was a 0.98 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 66,532 shares of company stock worth $3,665,786. 5.40% of the stock is currently owned by corporate insiders.

Protagonist Therapeutics Stock Up 2.8 %

NASDAQ PTGX opened at $45.62 on Wednesday. Protagonist Therapeutics, Inc. has a fifty-two week low of $24.78 and a fifty-two week high of $60.60. The business has a 50 day moving average price of $45.84 and a two-hundred day moving average price of $42.85. The stock has a market cap of $2.80 billion, a PE ratio of 17.15 and a beta of 2.30.

Protagonist Therapeutics (NASDAQ:PTGX) last released its quarterly earnings results on Friday, February 21st. The company reported $1.98 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $2.07. The business had revenue of $170.64 million during the quarter, compared to analyst estimates of $56.65 million. Protagonist Therapeutics had a net margin of 52.76% and a return on equity of 34.68%. Sell-side analysts anticipate that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on PTGX shares. Wedbush reaffirmed an “outperform” rating and issued a $70.00 price objective on shares of Protagonist Therapeutics in a research report on Friday, March 28th. JPMorgan Chase & Co. lifted their price target on Protagonist Therapeutics from $53.00 to $57.00 and gave the company an “overweight” rating in a report on Tuesday, March 4th. JMP Securities reissued a “market outperform” rating and issued a $58.00 target price on shares of Protagonist Therapeutics in a research report on Friday, February 7th. HC Wainwright restated a “buy” rating and issued a $80.00 target price on shares of Protagonist Therapeutics in a report on Thursday, April 10th. Finally, Truist Financial increased their price target on shares of Protagonist Therapeutics from $60.00 to $76.00 and gave the stock a “buy” rating in a research note on Tuesday, March 11th. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Protagonist Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $65.44.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.